Study Overview: This research is testing a new drug called XmAb541 for people with advanced solid tumors. The main goal is to see if XmAb541 is safe and to find the best dose to use in further studies. The study will also check how this drug affects the tumors.

Eligibility: To join, you must be at least 18 years old (15 for certain tumors) and have specific types of cancer such as ovarian or endometrial cancer. You should have tried other treatments that are no longer working for you. You need to be in good enough health, with a life expectancy of at least 3 months, and have proper liver, kidney, and bone marrow function.

Exclusions: You cannot join if you've used a similar drug targeting CLDN6 before, have certain types of ovarian cancer, or have active brain cancer. Autoimmune diseases, recent use of strong medications like steroids, serious heart, lung, or digestive issues, or certain infections like hepatitis C or B can also disqualify you.

• Study Duration: The length of the study can vary depending on individual response to the drug.
• Visits Required: Participants will need to attend multiple study visits for monitoring.
• Compensation: Details about compensation are typically provided during the initial study briefing.